Our top pick for
Sachem Capital Corp is a reit-mortgage business based in the US. Sachem Capital shares (SACH) are listed on the NYSE MKT and all prices are listed in US Dollars. Sachem Capital employs 12 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$5.93|
|52-week range||$3.61 - $6.35|
|50-day moving average||$5.44|
|200-day moving average||$5.20|
|Wall St. target price||$6.50|
|Dividend yield||$0.6 (10.1%)|
|Earnings per share (TTM)||$0.40|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||-3.58%|
|1 month (2021-09-27)||12.52%|
|3 months (2021-07-27)||16.27%|
|6 months (2021-04-27)||13.60%|
|1 year (2020-10-26)||45.48%|
|2 years (2019-10-25)||28.91%|
|3 years (2018-10-26)||39.12%|
|5 years (2016-10-23)||N/A|
Valuing Sachem Capital stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sachem Capital's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sachem Capital's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Sachem Capital shares trade at around 14x recent earnings.
|Revenue TTM||$13.9 million|
|Operating margin TTM||69.26%|
|Gross profit TTM||$13.1 million|
|Return on assets TTM||4.19%|
|Return on equity TTM||7.98%|
|Market capitalisation||$163.7 million|
TTM: trailing 12 months
There are currently 102,633 Sachem Capital shares held short by investors – that's known as Sachem Capital's "short interest". This figure is 68.5% up from 60,912 last month.
There are a few different ways that this level of interest in shorting Sachem Capital shares can be evaluated.
Sachem Capital's "short interest ratio" (SIR) is the quantity of Sachem Capital shares currently shorted divided by the average quantity of Sachem Capital shares traded daily (recently around 342110). Sachem Capital's SIR currently stands at 0.3. In other words for every 100,000 Sachem Capital shares traded daily on the market, roughly 300 shares are currently held short.
However Sachem Capital's short interest can also be evaluated against the total number of Sachem Capital shares, or, against the total number of tradable Sachem Capital shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sachem Capital's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Sachem Capital shares in existence, roughly 0 shares are currently held short) or 0.0041% of the tradable shares (for every 100,000 tradable Sachem Capital shares, roughly 4 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sachem Capital.
Find out more about how you can short Sachem Capital stock.
Dividend payout ratio: 1.17% of net profits
Recently Sachem Capital has paid out, on average, around 1.17% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 8.3% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Sachem Capital shareholders could enjoy a 8.3% return on their shares, in the form of dividend payments. In Sachem Capital's case, that would currently equate to about $0.6 per share.
While Sachem Capital's payout ratio might seem low, this can signify that Sachem Capital is investing more in its future growth.
Sachem Capital's most recent dividend payout was on 29 July 2021. The latest dividend was paid out to all shareholders who bought their shares by 21 October 2021 (the "ex-dividend date").
Over the last 12 months, Sachem Capital's shares have ranged in value from as little as $3.6065 up to $6.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Sachem Capital's is 1.2651. This would suggest that Sachem Capital's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Sachem Capital Corp. operates as a real estate finance company. The company is involved in the originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located primarily in Connecticut. It offers loans to real estate investors to fund their acquisition, renovation, rehabilitation, development, and/or improvement of residential or commercial properties. The company has elected to be taxed as a real estate investment trust (REIT) and would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. Sachem Capital Corp. was founded in 2010 and is based in Branford, Connecticut.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.